Transforming
HPV Care
First-in-class small molecule antivirals to treat HPV cancers and premalignant infections
Kovina Therapeutics is a preclinical stage biotechnology company developing targeted antiviral therapeutics designed to eliminate
Human Papillomavirus (HPV) driven cancers and premalignant infections caused by HPV.
HPV causes cancer
An estimated 630,000 HPV-related malignancies are diagnosed each year, representing 5% of the cancer burden worldwide.
Most cervical and oral cancers are caused by HPV
HPV causes nearly all cervical and the majority of oropharyngeal cancers. Available treatments—surgery, radiation, chemotherapy, and immunotherapy—often come with significant side effects.
HPV vaccine does not treat existing HPV cancers or infections
The HPV vaccine prevents new infections but does not treat HPV induced cancers or the millions of existing HPV infections such as cervical and anal dysplasia that can progress to cancer.
Our unique antiviral specifically targets the HPV E6 oncogene
infected cells
Our commitment to patients
Kovina is committed to providing patients infected with HPV novel treatment options not available in the market today. For patients living with HPV, Kovina’s development efforts provide hope for a non-surgical option to treat cancers and premalignant infections caused by HPV.
Meet the team of leaders and experts behind our science
Our board and scientific advisors bring deep expertise to guide Kovina’s strategy and science.
Investors and Partners
Backed by premier academic, institutional, and nonprofit partners: validating our science and strategic vision.
Grantors
Discover our latest news
Get in touch with our team
Kovina Therapeutics is a preclinical stage biotechnology company developing targeted antiviral therapeutics designed to eliminate
Human Papillomavirus (HPV) driven cancers and premalignant infections caused by HPV.